Company NanoViricides Inc OTC Bulletin Board

Equities

US6300871042

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

14/05	NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV	CI
08/05	NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox	CI

NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. It is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.

Managers	Title	Age	Since
Anil Diwan CEO	Chief Executive Officer	66	01/05/01
Meeta Vyas DFI	Director of Finance/CFO	66	13/13/13
Jayant Tatake CTO	Chief Tech/Sci/R&D Officer	-	03/10/03
Randall Barton CTO	Chief Tech/Sci/R&D Officer	-	03/10/03

Members of the board	Title	Age	Since
Brian Zucker BRD	Director/Board Member	62	13/20/13
Anil Diwan CEO	Chief Executive Officer	66	01/05/01
Makarand Jawadekar BRD	Director/Board Member	73	07/20/07
Theodore Rokita BRD	Director/Board Member	54	15/20/15

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	11,779,000	11,235,047 ( 95.38 %)	0	88.68 %
Stock B	0	890,511	0	0

Name	Equities	%	Valuation
Theracour Pharma, Inc. 3.998 %	470,959	3.998 %	522 764 $
Vanguard Global Advisers LLC 3.892 %	458,416	3.892 %	508 842 $
BlackRock Institutional Trust Co. NA 1.348 %	158,752	1.348 %	176 215 $
Compagnie Lombard Odier SCmA 1.273 %	150,000	1.273 %	166 500 $
Geode Capital Management LLC 0.9295 %	109,489	0.9295 %	121 533 $
Renaissance Technologies LLC 0.7174 %	84,500	0.7174 %	93 795 $
Bridgeway Capital Management LLC 0.5012 %	59,039	0.5012 %	65 533 $
STATE STREET CORPORATION 0.3558 %	41,906	0.3558 %	46 516 $
City National Bank (Los Angeles, California) 0.2592 %	30,535	0.2592 %	33 894 $
Northern Trust Investments, Inc.(Investment Management) 0.2508 %	29,546	0.2508 %	32 796 $

Name	Equities	%	Valuation
Theracour Pharma, Inc. 137.70 %	681,859	137.70 %	756 863 $
Anil Diwan 23.56 %	116,683	23.56 %	129 518 $
Meeta Vyas 3.279 %	16,237	3.279 %	18 023 $

NanoViricides, Inc.

1 Controls Drive

06484, Shelton

+203 937 6137

http://www.nanoviricides.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+7.20%	11TCr
REGENERON PHARMACEUTICALS, INC.	+10.97%	11TCr
ARGENX SE	+0.84%	2.23TCr
BIONTECH SE	-12.18%	2.22TCr
GENMAB A/S	-5.61%	1.94TCr
WUXI APPTEC CO., LTD.	-37.85%	1.79TCr
BEIGENE, LTD.	-5.59%	1.72TCr
NEUROCRINE BIOSCIENCES, INC.	+6.95%	1.43TCr
SAREPTA THERAPEUTICS, INC.	+35.07%	1.25TCr

Bio Therapeutic Drugs